

## TO THE SPANISH SECURITIES MARKET COMMISSION

Pursuant to the provisions of article 228 of the consolidated text of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, and its implementing regulations, Kerry Iberia Taste & Nutrition, S.L.U. ("**Kerry**"), an investment vehicle wholly-owned by Kerry Group plc, reports the following

### OTHER RELEVANT INFORMATION

In connection with the application for authorisation of the voluntary tender offer (the "**Offer**") launched by Kerry for all of the shares of Biosearch, S.A. ("**Biosearch**"), filed and published as an inside information notice (*comunicación de información privilegiada*) on 15 February 2021 (registration number 020.434) and admitted for processing by the Spanish Securities Market Commission (*Comisión Nacional del Mercado de Valores*) on 2 March 2021, it is hereby stated that, on 16 March 2021, the Spanish Competition and Markets National Commission (*Comisión Nacional de los Mercados y la Competencia*) has resolved, pursuant to article 57.2.a) of Law 15/2007, of 3 July, on the Competition Defense, to authorise the business concentration consisting of the potential acquisition of control over Biosearch by Kerry (file C/1169/21).

Consequently, one of the conditions to which the Offer is subject —namely, that Kerry obtain the relevant authorisations, non-objection resolutions or verifications with regard to antitrust—, has been fulfilled.

For all due purposes.

Madrid, 23 March 2021

**Kerry Iberia Taste & Nutrition, S.L.U.**

Ronan Deasy

Joint and several director